Literature DB >> 22553724

Experimental study on the photodynamic treatment of choroidal neovasculization with nanophthalocyanine photosensitizer.

Song-Yi Wu1, Guo-Xing Xu, Yi-Ru Peng, Xiao-Fang Zhou, Jian Guo.   

Abstract

AIM: To investigate the therapeutic effects of nanophthalocyanine photosensitizers on an experimental rat choroidal neovescularization (CNV) model, as well as to evaluate the cytotoxicity of which on human retinal pigment epithelia (HRPE) and human retinal endothelial cells (HRECs).
METHODS: Two types of photosensitizers, G(1)-ZnPc(COOH)(8) and G(1)-ZnPc(COOH)(8)/m respectively, were administrated for photodynamic therapy (PDT) after a successful establishment of CNV model on Brown-Norway (BN) rats via fundus photocoagulation. The therapeutic effects of the two drugs were assessed through optical coherence tomography (OCT), fluorescein fundus angiography (FFA) and transmission electron microscopy (TEM). For cytotoxicity tests, cell counting kit-8 (CCK-8) assays and changes of mitochondrial transmembrane potential (△Ψm) were conducted on HRPE and HRECs after initial uptake of the two drugs.
RESULTS: Both photosensitizers demonstrated an improvement of vascular leakage and closure of CNV 1 week after PDT as confirmed by fundus image, OCT, FFA and TEM. Two weeks after PDT, G(1)-ZnPc(COOH)(8)/m showed a better CNV closure effect versus G(1)-ZnPc(COOH)(8) (P<0.05). A significant difference (P<0.01) was found in uptake of the two drugs in HRPE and HRECs, with no difference between the drugs (P>0.05). Both photosensitizers showed cytotoxicity on HRPE, but G(1)-ZnPc(COOH)(8)/m induced a lower cell viability.
CONCLUSION: G(1)-ZnPc(COOH)(8)/m mediated PDT is better than G(1)-ZnPc(COOH)(8) in CNV closure and also have the advantage of fast metabolism leading to less side effect.

Entities:  

Keywords:  carrier; choroidal neovascularization; nanoparticles; photodynamic treatment; phthalocyanine; retina pigment epithelial cells

Year:  2011        PMID: 22553724      PMCID: PMC3340787          DOI: 10.3980/j.issn.2222-3959.2011.06.01

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN: 2222-3959            Impact factor:   1.779


  18 in total

Review 1.  Mitochondria-based photodynamic anti-cancer therapy.

Authors:  J Morgan; A R Oseroff
Journal:  Adv Drug Deliv Rev       Date:  2001-07-02       Impact factor: 15.470

Review 2.  Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies.

Authors:  Jayakrishna Ambati; Balamurali K Ambati; Sonia H Yoo; Sean Ianchulev; Anthony P Adamis
Journal:  Surv Ophthalmol       Date:  2003 May-Jun       Impact factor: 6.048

3.  Long term results after transpupillary thermotherapy in eyes with occult choroidal neovascularisation associated with age related macular degeneration: a prospective trial.

Authors:  U Stolba; I Krebs; P D Lamar; T Aggermann; D Gruber; S Binder
Journal:  Br J Ophthalmol       Date:  2006-02       Impact factor: 4.638

Review 4.  Drug targeting: where are we now and where are we going?

Authors:  R Duncan
Journal:  J Drug Target       Date:  1997       Impact factor: 5.121

5.  Verteporfin photodynamic therapy of choroidal neovascularization in angioid streaks: one-year results of a prospective case series.

Authors:  Andrew C Browning; A K K Chung; F Ghanchi; S P Harding; M Musadiq; S J Talks; Y C Yang; W M Amoaku
Journal:  Ophthalmology       Date:  2005-07       Impact factor: 12.079

6.  Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study.

Authors:  Jeffrey S Heier; David S Boyer; Thomas A Ciulla; Philip J Ferrone; J Michael Jumper; Ronald C Gentile; Debbi Kotlovker; Carol Y Chung; Robert Y Kim
Journal:  Arch Ophthalmol       Date:  2006-11

7.  The effect of nitric oxide on cell respiration: A key to understanding its role in cell survival or death.

Authors:  B Beltrán; A Mathur; M R Duchen; J D Erusalimsky; S Moncada
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-19       Impact factor: 11.205

8.  Photodynamic therapy with verteporfin in ocular histoplasmosis: uncontrolled, open-label 2-year study.

Authors:  Philip J Rosenfeld; David A Saperstein; Neil M Bressler; Troy A Reaves; Michel Sickenberg; Robert H Rosa; Paul Sternberg; Thomas M Aaberg; Thomas M Aaberg
Journal:  Ophthalmology       Date:  2004-09       Impact factor: 12.079

9.  Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study.

Authors:  Jeffrey S Heier; Andrew N Antoszyk; Peter Reed Pavan; Steven R Leff; Philip J Rosenfeld; Thomas A Ciulla; Richard F Dreyer; Ronald C Gentile; Judy P Sy; Gary Hantsbarger; Naveed Shams
Journal:  Ophthalmology       Date:  2006-02-14       Impact factor: 12.079

10.  Ten-year incidence and progression of age-related maculopathy: The Beaver Dam eye study.

Authors:  Ronald Klein; Barbara E K Klein; Sandra C Tomany; Stacy M Meuer; Guan-Hua Huang
Journal:  Ophthalmology       Date:  2002-10       Impact factor: 12.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.